Posts tagged with: malaria

Ray’s post pointed to something that’s been bugging me about Jim Wallis’ “What Would Jesus Cut?” campaign. As with the “What Would Jesus Drive?” campaign (“Transportation is a moral issue.” What isn’t these days?), Wallis’ campaign assumes the moral high ground by appropriating the Holy Name of Jesus Christ to advance his highly politicized, partisan advocacy. Jesus becomes an advertising slogan. And what is implicit here is that those who oppose Wallis are somehow at odds with the Gospel of Christ; those who agree with him are on Christ’s side and especially as it concerns “the least of these.”

But watch the video above and listen to the language of this MSNBC program host. What Wallis and his organization have done is give occasion for the use of Christ’s name for the most partisan, mocking and disrespectful purposes. Wallis should be ashamed of himself, but instead he lets this all pass so he can right away get to his simplistic talking points about “the budget as a moral document.” He arrogantly does this as the voice for the “faith community.”

Did I say simplistic? I should have added “dishonest” to my description of what Wallis is doing.

No serious person would take Wallis’ sound bites or the Sojourners campaign as a real help to understanding our nation’s grave budget and debt problems. In that respect, what Wallis is doing is aggravating a problem that has cried out for honest, bipartisan cooperation for many years. He makes inflammatory assertions about cuts to programs for nutrition, malarial bed nets, and the like, and generally raises false alarms about budget cutters abandoning “the most vulnerable.” Really? If this were true, it would cast those Christians on the other side of Wallis — those who honestly believe we need to do something serious about the budget and mounting debt — as haters of the poor. Look at the White House chart on the budget and show me where this abandonment is happening. Just the opposite.

And all these vague, unattributed assertions, like the bed nets. If you don’t see it the way Wallis sees it, you must be indifferent to children dying of malaria. Right? That’s insulting to say the least. How many mosquito nets flow into Africa annually? Where do they come from? What share of these is funded by U.S. taxpayers? Are they effective? We don’t get answers to these questions. Maybe Wallis should read this article in the left leaning Guardian newspaper that explains why “Mosquito nets can’t conquer malaria.” How is malaria defeated? Economic growth.

Against his claims of abandoning the poor, Wallis harps on defense spending. Again, this is a dishonest diversion. Defense spending is not the main problem as this chart vividly shows (HT: Heritage Foundation).

Should defense spending be treated as a sacred cow? No. Is there waste in the defense budget? Undoubtedly. But let’s not make vague assertions about children going hungry because of redundant or unneeded military programs.

What’s more, Wallis seems to be impervious to the fact that spending on welfare and War on Poverty programs has been a massive and costly failure. His use of anecdote and selectively trivial factoids serves as a smokescreen for this reality. Is is possible that government nutrition programs might be wasteful or redundant? He doesn’t seem to be aware of that possibility. In a recent report on duplication in government programs, the GAO said this about nutrition programs:

Domestic food and nutrition assistance is provided through a decentralized system of primarily 18 different federal programs that shows signs of overlap and inefficient use of resources. [But] not enough is known about the effectiveness of many of these programs. Research suggests that participation in 7 of the 18 programs— including the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC), the National School Lunch Program, the School Breakfast Program, and SNAP—is associated with positive health and nutrition outcomes consistent with programs’ goals, such as raising the level of nutrition among low-income households, safeguarding the health and well-being of the nation’s children, and strengthening the agricultural economy. Yet little is known about the effectiveness of the remaining 11 programs because they have not been well studied.

Reality gets complicated. Talking points are easier. Writing in 2005, Washington Post columnist George Will described how a freshman Sen. Barack Obama used a string of “old banalities” to attack the Bush administration for not doing enough to alleviate the suffering caused by Hurricane Katrina. Will wrote:

[Obama] included the requisite lament about the president’s inadequate “empathy” and an amazing criticism of the government’s “historic indifference” and its “passive indifference” that “is as bad as active malice.” The senator, 44, is just 30 months older than the “war on poverty” that President Johnson declared in January 1964. Since then the indifference that is as bad as active malice has been expressed in more than $6.6 trillion of anti-poverty spending, strictly defined.

At least Obama had the decency not to invoke the name of the Lord. As for the “What Would Jesus Cut?” campaign, the “faith community” hasn’t been spared that.

Blog author: jballor
Wednesday, April 25, 2007

Today is Malaria Awareness Day. Today’s edition of Zondervan>To the Point has a plethora of related links (look under “Extra Points”).

Be sure to also check out Acton’s award-winning ad campaign, which focuses in part on impacting malaria.

Blog author: jballor
Thursday, December 28, 2006

Our series on the year in review continues with the third fourth of 2006:


“Isn’t the Cold War Over?” David Michael Phelps

I’ve got an idea for a new sitcom. Titled, Hugo and Vladi, it details the zany adventures of two world leaders, one of whom (played by David Hyde Pierce) struggles to upkeep his image of a friendly, modern European diplomat while his goofball brother-in-law (played by George Lopez) keeps screwing it up for him by spouting off vitriolic Soviet rhetoric and threatening all of Western civilization with his agressive (but loveable) arms sales and seizures of private oil companies….


“Wealth, Envy, and Happiness,” Jordan J. Ballor

This natural tendency to compare our financial status to others is an expression of money envy, which also finds expression, at least in part, in the concern about income disparities….


“DDT Breakthrough at the WHO,” John Couretas

Africans are hailing a major shift in policy at the World Health Organization: A recommendation for the limited, indoor use of DDT to control malaria….

Blog author: jballor
Monday, September 25, 2006

This week, University of Chicago faculty members Richard A. Posner and Gary S. Becker discuss and debate the relationship between DDT and the fight against malaria on their blog.

As a self-proclaimed “strong environmentalist” who supports “the ban on using DDT as a herbicide,” Posner writes first about the contemporary decline in genetic diversity due in large part to the rate of species extinction. (Posner has issued a correction: “Unforgivably, I referred to DDT as a ‘herbicide.’ It is, of course, a pesticide. A herbicide is used to destroy weeds and other plants.” Presumably enough DDT would kill plants, and also presumably Posner would oppose such a use. But even so, Posner’s clarification is duly noted.)

“The decline in genetic diversity–to which spraying crops with DDT would be contributing significantly if it were permitted–is alarming even from a purely selfish anthropocentric perspective,” says Posner, “Because such diversity, like other forms of diversification, performs an important insurance function.”

Even so, Posner notes, “The quantities of DDT used in spraying indoor houses in Subsaharan Africa (where 90 percent of malaria deaths occur) are so minute that the environmental effects are inconsequential.” Despite the ban on DDT as an herbicide, an exception allows its use in the fight against malaria. “The puzzle is why the exception is so rarely invoked,” says Posner, because the use of malaria in residual indoor spraying is so cost-effective when compared to many other tools in the fight against malaria.

Comparing the threat of AIDS versus that of malaria, Posner concludes, “Considering how much cheaper and easier it would be to (largely) eliminate malaria than to eliminate AIDS (which would require behavioral changes to which there is strong cultural resistance in Africa), the failure of the African countries, the World Health Organization, the World Bank, and private foundations and other nongovernmental organizations to eliminate most malaria by means of indoor spraying with DDT is a remarkable political failure.”

I might also observe that at one point Posner comments, “Not that eliminating childhood deaths from malaria (I have seen an estimate that 80 percent of malaria deaths are of children) would be a completely unalloyed boon for Africa, which suffers from overpopulation.” A commenter rightly takes Posner to task for this statement, saying, “Economic analysis of social problems can be useful and even compelling. The foregoing, however, seems a bit cold-blooded even for an economist. I suspect and hope Posner doesn’t really mean it.”

Gary Becker provides an excellent narrative of the relationship between DDT and malaria in his post. He also points out, “One unintended consequence of the DDT ban was a devastating comeback by malaria and some other diseases after they had been in retreat. Other pesticides that replaced DDT have been much less effective at reducing malaria and other diseases transmitted by insects.”

“I am an ‘environmentalist’,” says Becker, “But I do not believe that all reasonable cost-benefit analysis should be suspended when discussing environmental issues. The ban on using DDT in houses to fight malaria is an example of environmentalism that lost all sense of proportion.”

For more on the campaign to bring back DDT to the malaria-fighting arsenal, check out Acton’s Impact ad project.

Blog author: jcouretas
Tuesday, September 19, 2006

Africans are hailing a major shift in policy at the World Health Organization: A recommendation for the limited, indoor use of DDT to control malaria.

The fight against the disease, which is a leading cause of death in the developing world, has been hobbled by a long running campaign by environmentalists to ban the insecticide, a campaign that resulted in millions of needless deaths.

The South African health ministry welcomed the policy shift, noting that its return to the use of DDT had reduced malaria deaths from 64,868 in 2000 to 7,754 in 2005.

Health ministry spokesman Sibani Mngadi said that the “incidence of malaria had decreased from 15 per 10,000 people in 2000 to two per 10,000 in 2005 in malaria-affected areas.”

On Friday, the WHO released a statement that, nearly 30 years after phasing out the indoor spraying of DDT, gave a “clean bill of health” to the use of DDT. The organization is “now recommending the use of indoor residual spraying (IRS) not only in epidemic areas but also in areas with constant and high malaria transmission, including throughout Africa.”

“The scientific and programmatic evidence clearly supports this reassessment,” said Dr Anarfi Asamoa-Baah, WHO Assistant Director-General for HIV/AIDS, TB and Malaria. “Indoor residual spraying is useful to quickly reduce the number of infections caused by malaria-carrying mosquitoes. IRS has proven to be just as cost effective as other malaria prevention measures, and DDT presents no health risk when used properly.”

Read Paul Driessen’s commentary on the Africa Fighting Malaria site on the WHO announcement:

In Kenya alone, 34,000 young children a year perish from malaria, says Health Minister Charity Ngilu. Uganda suffers 100,000 deaths annually, notes Minister of Health Dr. Stephen Malinga — the equivalent of a jetliner with 275 people slamming into its Rwenzori Mountains every day.

Africa has 400 million cases of acute malaria per year; up to 2 million die. Countless millions are too sick to work or go to school, countless millions more must stay home to care for them, and meager family savings are exhausted on anti-malaria drugs.

The Wall Street Journal (subscription required) neatly summed up the issue yesterday:

Malaria is the number one killer of pregnant women and children in Africa and among the top killers in Asia and South America. It’s long been known that DDT is the cheapest and most effective way to contain the disease, which is spread by infected mosquitoes. But United Nations health agencies and others have for decades resisted employing DDT under pressure from anti-pesticide environmentalists. After tens of millions of preventable malarial deaths in these poor countries, it’s nice to see WHO finally come to its senses.

Click on the image above to vist Acton’s special Impact Malaria! Web page and to download the institute’s “Let Us Spray” print ad. The ad, which has run in Christianity Today and WORLD Magazine, is available for use in church bulletins, student newspapers and other publications — free of charge.

Blog author: jballor
Monday, August 14, 2006

“Scientists have discovered a way to help stop the spread of malaria by genetically altering a bacterium that infects about 80 percent of the world’s insects. Malaria is primarily transmitted through mosquito bites and kills more than a million people every year.”

Source: “Genetically Altered Bacteria Could Block Malaria Transmission,” by Lisa Pickoff-White, The National Academies, Science in the Headlines, August 2, 2006.

HT: Zondervan “To the Point”

For more on the fight against malaria, visit Acton’s Impact campaign page.

At least, the title of this post is typical of the mantra against the practices of drug pharmaceutical companies, according to Peter W. Huber’s “Of Pills and Profits: In Defense of Big Pharma,” in Commentary magazine (HT: Arts & Letters Daily).

Huber, a senior fellow of the Manhattan Institute, summarizes in brief the anti-drug company argument, and then goes on to examine what truth there is in such claims. He says of the difference between creating and administering drugs, “Getting drug policy right depends mainly on getting that difference straight—the difference, that is, between ministering to the sick and making medicines—and grasping its implications from the start. Big Pharma’s critics do not even try.”

He goes on:

Pricing is indeed the key. Whether the first pill typically costs $100 million or $1 billion to develop, replicating it costs less—a thousand times less, or perhaps a million times less. This slope—precipice, really—is far steeper than most of the other hills and valleys of economic life. It complicates things immeasurably. It also largely explains the gulf between the industry’s perception of reality and that of the critics.

Huber gives some explanation of the function of the price mechanism in pharmaceutical markets, and says, “Economists have established—as rigorously as things ever get established by the dismal science—that there is no efficient price, no ‘right’ price. Any scheme is, from one perspective or another, inefficient, unreasonable, or worse.” He argues that the high prices for boutique drugs like Viagra in the developed world help fund the provision of desperately needed drugs in the developing world. This is the situation created by so-called “price discrimination”.

The situation he says, is similar to that of airline travel: “Business travelers get soaked, college students fly almost for free, and the jumble of prices in between drives most people nuts. But the planes are packed full, and that drives the average price of a ticket way down. The rich fly, and the much less rich fly, too.” There is, I would think, a similar model at play in the work of plastic surgeons who charge Hollywood millionaires huge sums to do face lifts and tummy tucks, and then use a portion of the money they make doing that to do pro bono work for burn victims and deformed children.

The complexity of the pricing situation is what critiques of drug companies tend to ignore. Concludes Huber, “This kind of behavior is not aberrant or anomalous—it is an inevitable and essential part of groping toward the right price where there is no right at the end of the tunnel. Somehow or other, the average price of the pill has to end up high enough to pay off the up-front cost.”

If Huber’s analysis is correct, it is interesting to see how a nonprofit drug company, like the one profiled in today’s New York Times article, “A Small Charity Takes Lead in Fighting a Disease,” fits into the picture. The NYT article itself exemplifies many of the criticisms against pharmaceuticals that Huber summarizes.

Huber points to the vagaries of government regulation and private insurance, which greatly affect the drug market. One explanation for the situation that a nonprofit drug company like OneWorld Health attempts to address is that “big drug companies shun some drugs and embrace others because, collectively, the FDA, doctors, patients, insurers, and juries push costs higher, and prices lower, on some categories of drugs and not on others, to the point where some make economic sense and some do not.”

Indeed, OneWorld Health is working with a drug for black fever that, according to the NYT, administered “a series of cheap injections was identified decades ago but then died in the research pipeline because there was no profit in it.” There is, effectively, a partnership at play between for profit and nonprofit drug companies. OneWorld Health didn’t develop the drug in the first place, but on that point is dependent on the work of for profits.

Huber says:

Universities and small biotechs license their innovations to Big Pharma because they lack the capital, scale, and expertise required for mass manufacturing, because they wouldn’t know how to sell the same drug five times in succession (to the FDA, doctors, patients, insurers, and juries), and because a vast and swampy system separates pharmaceutical innovation from the treatment of real patients at prices that will cover cost and earn a profit. The little guys just don’t have what it takes to finish the job.

But OneWorld Health, in the case of the drug mentioned above (paromomycin), “has conducted the medical trials needed to prove that the drug is safe and effective. Now it is on the verge of getting final approval from the Indian government. A course of treatment with the drug is expected to cost just $10, and experts say it could virtually eliminate the disease. If approval is granted as expected this fall, it will be the first time a charity has succeeded in ushering a drug to market.”

Huber concludes that in the future “we will fare better, much better, if we streamline regulation, curb litigation, and unleash prices to make vaccines as alluring to Big Pharma as Viagra and Vaniqa.” But in the meantime, it may be that efforts like OneWorld Health can help at least some of those who fall through the cracks. Says Dr. Ahvie Herskowitz, one of the backers of OneWorld Health, “We fill a gap pharma companies cannot because they have to make a profit.”

And on the biggest obstacle to getting vaccines and drugs like paromomycin to those who need it, for profit and nonprofit drug companies seem to agree: “The government will be the biggest challenge,” says Dr. C. P. Thakur, a former Indian health minister who oversaw a OneWorld Health trial of paromomycin.